Adverum Biotechnologies, Inc. (ADVM): Price and Financial Metrics


Adverum Biotechnologies, Inc. (ADVM): $0.83

-0.03 (-3.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADVM to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ADVM POWR Grades


  • Value is the dimension where ADVM ranks best; there it ranks ahead of 58.81% of US stocks.
  • ADVM's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • ADVM's current lowest rank is in the Stability metric (where it is better than 7.8% of US stocks).

ADVM Stock Summary

  • Adverum Biotechnologies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.89% of US listed stocks.
  • With a price/sales ratio of 18.19, Adverum Biotechnologies Inc has a higher such ratio than 92.23% of stocks in our set.
  • With a year-over-year growth in debt of 341.62%, Adverum Biotechnologies Inc's debt growth rate surpasses 96.39% of about US stocks.
  • Stocks that are quantitatively similar to ADVM, based on their financial statements, market capitalization, and price volatility, are BCYC, API, ABEO, ENTX, and CYCN.
  • Visit ADVM's SEC page to see the company's official filings. To visit the company's web site, go to www.adverum.com.

ADVM Valuation Summary

  • In comparison to the median Healthcare stock, ADVM's price/sales ratio is 736.84% higher, now standing at 31.8.
  • Over the past 86 months, ADVM's EV/EBIT ratio has gone up 49.6.
  • ADVM's EV/EBIT ratio has moved up 49.6 over the prior 86 months.

Below are key valuation metrics over time for ADVM.

Stock Date P/S P/B P/E EV/EBIT
ADVM 2021-08-31 31.8 0.6 -1.7 -2.3
ADVM 2021-08-30 31.3 0.6 -1.7 -2.2
ADVM 2021-08-27 31.4 0.6 -1.7 -2.2
ADVM 2021-08-26 30.1 0.6 -1.6 -2.2
ADVM 2021-08-25 31.4 0.6 -1.7 -2.2
ADVM 2021-08-24 30.7 0.6 -1.7 -2.2

ADVM Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at -36.69%.
  • The 2 year cash and equivalents growth rate now stands at -14.11%.
  • The 3 year net cashflow from operations growth rate now stands at -36.35%.
ADVM's revenue has moved up $5,624,000 over the prior 49 months.

The table below shows ADVM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 7.5 -104.24 -148.763
2021-06-30 7.5 -104.988 -138.17
2021-03-31 7.5 -87.98 -123.037
2020-12-31 0 -79.291 -117.507
2020-09-30 0 -71.902 -98.8
2020-06-30 0.25 -54.888 -87.149

ADVM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ADVM has a Quality Grade of C, ranking ahead of 36.31% of graded US stocks.
  • ADVM's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
  • REGN, PRGO, and ORMP are the stocks whose asset turnover ratios are most correlated with ADVM.

The table below shows ADVM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.015 1 -0.294
2021-03-31 0.017 1 -0.306
2020-12-31 0.000 NA -0.331
2020-09-30 0.000 NA -0.345
2020-06-30 0.001 1 -0.416
2020-03-31 0.001 1 -0.447

ADVM Price Target

For more insight on analysts targets of ADVM, see our ADVM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $3.57 Average Broker Recommendation 1.94 (Hold)

ADVM Stock Price Chart Interactive Chart >

Price chart for ADVM

ADVM Price/Volume Stats

Current price $0.83 52-week high $3.86
Prev. close $0.86 52-week low $0.80
Day low $0.82 Volume 603,200
Day high $0.89 Avg. volume 1,114,779
50-day MA $1.16 Dividend yield N/A
200-day MA $1.73 Market Cap 81.58M

Adverum Biotechnologies, Inc. (ADVM) Company Bio


Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company was founded in 2006 and is based in Menlo Park, California.


ADVM Latest News Stream


Event/Time News Detail
Loading, please wait...

ADVM Latest Social Stream


Loading social stream, please wait...

View Full ADVM Social Stream

Latest ADVM News From Around the Web

Below are the latest news stories about Adverum Biotechnologies Inc that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Insiders who bought in the last 12 months lose an additional US$367k as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$136m

The recent price decline of 12% in Adverum Biotechnologies, Inc.'s ( NASDAQ:ADVM ) stock may have disappointed insiders...

Yahoo | February 15, 2022

Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer

- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration -

GlobeNewswire | February 7, 2022

Adverum Biotechnologies names new CMO

Adverum Biotechnologies (ADVM) has appointed ophthalmologist Richard Beckman, M.D., as the company''s new chief medical officer. Most recently, Dr

Seeking Alpha | February 7, 2022

Thinking about buying stock in Jaguar Health, Evofem Biosciences, Adverum Biotechnologies, FREYR Battery, or Planet Labs?

NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on Benzinga.com

Benzinga | January 12, 2022

Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company’s chief development officer. Dr. Seyedkazemi will serve as a member of Adverum’s executive committee and will report to Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. Dr. Seyedkaze

Yahoo | January 6, 2022

Read More 'ADVM' Stories Here

ADVM Price Returns

1-mo -27.19%
3-mo -36.15%
6-mo N/A
1-year -75.73%
3-year -91.00%
5-year -68.68%
YTD -52.84%
2021 -83.76%
2020 -5.90%
2019 265.71%
2018 -10.00%
2017 20.69%

Continue Researching ADVM

Here are a few links from around the web to help you further your research on Adverum Biotechnologies Inc's stock as an investment opportunity:

Adverum Biotechnologies Inc (ADVM) Stock Price | Nasdaq
Adverum Biotechnologies Inc (ADVM) Stock Quote, History and News - Yahoo Finance
Adverum Biotechnologies Inc (ADVM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.613 seconds.